Ontstaan van gewrichtsontstekingen bij patiënten met psoriasis

Development of Arthritis in Psoriasis Patients for Early Rheumatological referral – Incidence

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON20950

Enrollment

250

Registered

2021-01-14

Start date

2020-12-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis, Psoriatic Arthritis

Interventions

None.

Eligibility

Inclusion criteria

Inclusion criteria: * Diagnosis of cutaneous psoriasis * Inclusion in DAPPER study * Age 16 years or above * Willing and able to comply with visits and study-related procedures * Provide signed informed consent (IC)

Exclusion criteria

Exclusion criteria: * Medical history with PsA * Medical history with other immune-mediated or auto-immune rheumatological disease. For example, but not limited to: rheumatoid arthritis, systemic vasculitis, axial spondyloarthritis. Gout, fibromyalgia or osteo-arthritis are not excluded.

Design outcomes

Primary

Measure	Time frame
Main study endpoint will be the incidence rate of PsA in Pso patients in the setting of a university dermatology outpatient clinic.	—

Secondary

Measure	Time frame
Secondary endpoints will be the predictive values of several markers to predict the chance of development of PsA.	—

Contacts

Public ContactTamara van Hal

Sint Maartenskliniek

t.vanhal@maartenskliniek.nl0623598182

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)